HSPB1P2

Across TCGA pan-cancer cohorts, HSPB1P2 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of HSPB1P2’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where HSPB1P2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types HSPB1P2 is over-expressed in tumor, although a few such as STAD and PRAD show the opposite, repressed pattern.

LIHC, KIRC, and LUSC are the cancer types where HSPB1P2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HSPB1P2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.811	<.001	9	view →
KIRC	Male	III,IV	+0.690	<.001	9	view →
LUSC	All	II,III,IV	+0.997	<.001	7	view →
KIRP	Male	II,III,IV	+0.767	<.001	7	view →
BRCA	All	III,IV	+0.636	<.001	6	view →
COAD	Female	All	+1.915	<.001	5	view →
LUAD	All	All	+0.304	.001	5	view →
CHOL	All	All	+0.543	.001	3	view →
STAD	All	All	−0.683	.032	2	view →
PRAD	All	All	−0.365	<.001	2	view →
HNSC	Male	All	+0.402	.035	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

HSPB1P2–LIHC

Open the LIHC breakdown →